MiR-101 sensitizes human nasopharyngeal carcinoma cells to radiation by targeting stathmin 1

Molecular Medicine Reports

Volumn 11, Issue 5, 2015, Pages 3330-3336

  Sun, Quanquan ^a   Liu, Tongxin ^a   Zhang, Tian ^a   Du, Shasha ^a   Xie, Guozhu ^a   Lin, Xiaoshan ^a   Chen, Longhua ^a   Yuan, Yawei ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

MicroRNA; MiR 101; Nasopharyngeal carcinoma; Radioresistance; Stathmin 1

Indexed keywords

MICRORNA 101; STATHMIN; MESSENGER RNA; MICRORNA; MIRN101 MICRORNA, HUMAN; STMN1 PROTEIN, HUMAN;

ARTICLE; AUTOPHAGY; CANCER RADIOTHERAPY; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; NASOPHARYNX CARCINOMA; PROTEIN EXPRESSION; RADIOSENSITIVITY; CELL SURVIVAL; GENE EXPRESSION REGULATION; GENETICS; NASOPHARYNGEAL NEOPLASMS; RADIATION RESPONSE; RADIATION TOLERANCE; RNA INTERFERENCE; TUMOR CELL LINE;

AUTOPHAGY; CELL LINE, TUMOR; CELL SURVIVAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; NASOPHARYNGEAL NEOPLASMS; RADIATION TOLERANCE; RNA INTERFERENCE; RNA, MESSENGER; STATHMIN;

EID: 84922287250     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2015.3221     Document Type: Article

References (30)

1. Wei WI and Sham JS: Nasopharyngeal carcinoma. Lancet 365: 2041-2054, 2005.
2. Lo KW, Chung GT and To KF: Deciphering the molecular genetic basis of NPC through molecular, cytogenetic, and epigenetic approaches. Semin Cancer Biol 22: 79-86, 2012.
3. Feng XP, Yi H, Li MY, Li XH, Yi B, Zhang PF, Li C, Peng F, Tang CE, Li JL, et al: Identification of biomarkers for predicting nasopharyngeal carcinoma response to radiotherapy by proteomics. Cancer Res 70: 3450-3462, 2010.
4. Lai SZ, Li WF, Chen L, Luo W, Chen YY, Liu LZ, Sun Y, Lin AH, Liu MZ and Ma J: How does intensity-modulated radiotherapy versus conventional two-dimensional radiotherapy influence the treatment results in nasopharyngeal carcinoma patients? Int J Radiat Oncol Biol Phys 80: 661-668, 2011.
5. Gupta AK, McKenna WG, Weber CN, Feldman MD, Goldsmith JD, Mick R, Machtay M, Rosenthal DI, Bakanauskas VJ, Cerniglia GJ, et al: Local recurrence in head and neck cancer: relationship to radiation resistance and signal transduction. Clin Cancer Res 8: 885-892, 2002.
6. Kim VN, Han J and Siomi MC: Biogenesis of small RNAs in animals. Nat Rev Mol Cell Biol 10: 126-139, 2009.
7. Frankel LB, Wen J, Lees M, Høyer-Hansen M, Farkas T, Krogh A, Jäättelä M and Lund AH: microRNA-101 is a potent inhibitor of autophagy. EMBO J 30: 4628-4641, 2011.
8. Bartel DP: microRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281-297, 2004.
9. Esquela-Kerscher A and Slack FJ: Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer 6: 259-269, 2006.
10. O'Day E and Lal A: MicroRNAs and their target gene networks in breast cancer. Breast Cancer Res 12: 201, 2010.
11. Zheng J, Deng J, Xiao M, Yang L, Zhang L, You Y, Hu M, Li N, Wu H, Li W, et al: A sequence polymorphism in miR-608 predicts recurrence after radiotherapy for nasopharyngeal carcinoma. Cancer Res 73: 5151-5162, 2013.
12. Zhang JX, Qian D, Wang FW, Liao DZ, Wei JH, Tong ZT, Fu J, Huang XX, Liao YJ, Deng HX, et al: microRNA-29c enhances the sensitivities of human nasopharyngeal carcinoma to cisplatin-based chemotherapy and radiotherapy. Cancer Lett 329: 91-98, 2013.
13. He XP, Shao Y, Li XL, Xu W, Chen GS, Sun HH, Xu HC, Xu X, Tang D, Zheng XF, et al: Downregulation of miR-101 in gastric cancer correlates with cyclooxygenase-2 overexpression and tumor growth. FEBS J 279: 4201-4212, 2012.
14. Luo L, Zhang T, Liu H, Lv T, Yuan D, Yao Y, Lv Y and Song Y: miR-101 and Mcl-1 in non-small-cell lung cancer: expression profile and clinical significance. Med Oncol 29: 1681-1686, 2012.
15. Schee K, Boye K, Abrahamsen TW, Fodstad \O and Flatmark K: Clinical relevance of microRNA miR-21, miR-31, miR-92a, miR-101, miR-106a and miR-145 in colorectal cancer. BMC Cancer 12: 505, 2012.
16. Wang R, Wang HB, Hao CJ, Cui Y, Han XC, Hu Y, Li FF, Xia HF and Ma X: miR-101 is involved in human breast carcinogenesis by targeting Stathmin1. PLoS One 7: e46173, 2012.
17. Zhang J, Han C, Zhu H, Song K and Wu T: miR-101 inhibits cholangiocarcinoma angiogenesis through targeting vascular endothelial growth factor (VEGF). Am J Pathol 182: 1629-1639, 2013.
18. Chen S, Wang H, Ng WL, Curran WJ and Wang Y: Radiosensitizing effects of ectopic miR-101 on non-small-cell lung cancer cells depend on the endogenous miR-101 level. Int J Radiat Oncol Biol Phys 81: 1524-1529, 2011.
19. Green LM, Reade JL and Ware CF: Rapid colorimetric assay for cell viability: application to the quantitation of cytotoxic and growth inhibitory lymphokines. J Immunol Methods 70: 257-268, 1984.
20. Xie G, Zhan J, Tian Y, Liu Y, Chen Z, Ren C, Sun Q, Lian J, Chen L, Ruan J, et al: Mammosphere cells from high-passage MCF7 cell line show variable loss of tumorigenicity and radioresistance. Cancer Lett 316: 53-61, 2012.
21. Mah LJ, El-Osta A and Karagiannis TC: gammaH2AX: a sensitive molecular marker of DNA damage and repair. Leukemia 24: 679-686, 2010.
22. Kong W, He L, Richards EJ, Challa S, Xu CX, Permuth-Wey J, Lancaster JM, Coppola D, Sellers TA, Djeu JY and Cheng JQ: Upregulation of miRNA-155 promotes tumour angiogenesis by targeting VHL and is associated with poor prognosis and triple-negative breast cancer. Oncogene 33: 679-689, 2014.
23. Oue N, Anami K, Schetter AJ, Moehler M, Okayama H, Khan MA, Bowman ED, Mueller A, Schad A, Shimomura M, et al: High miR-21 expression from FFPE tissues is associated with poor survival and response to adjuvant chemotherapy in colon cancer. Int J Cancer 134: 1926-1934, 2014.
24. Schliekelman MJ, Gibbons DL, Faca VM, Creighton CJ, Rizvi ZH, Zhang Q, Wong CH, Wang H, Ungewiss C, Ahn YH, et al: Targets of the tumor suppressor miR-200 in regulation of the epithelial-mesenchymal transition in cancer. Cancer Res 71: 7670-7682, 2011.
25. Hu X, Guo J, Zheng L, Li C, Zheng TM, Tanyi JL, Liang S, Benedetto C, Mitidieri M, Katsaros D, Zhao X, Zhang Y, Huang Q and Zhang L: The heterochronic microRNA let-7 inhibits cell motility by regulating the genes in the actin cytoskeleton pathway in breast cancer. Mol Cancer Res 11: 240-250, 2013.
26. Choi AM, Ryter SW and Levine B: Autophagy in human health and disease. N Engl J Med 368: 651-662, 2013.
27. Wang Y, Yin W and Zhu X: Blocked autophagy enhances radiosensitivity of nasopharyngeal carcinoma cell line CNE-2 in vitro. Acta Otolaryngol 134: 105-110, 2014.
28. Luo C, Merz PR, Chen Y, Dickes E, Pscherer A, Schadendorf D and Eichmüller SB: miR-101 inhibits melanoma cell invasion and proliferation by targeting MITF and EZH2. Cancer Lett 341: 240-247, 2013.
29. Yan D, Ng WL and Zhang X, Wang P, Zhang Z, Mo YY, Mao H, Hao C, Olson JJ, Curran WJ and Wang Y: Targeting DNA-PKcs and ATM with miR-101 sensitizes tumors to radiation. PLoS One 5: e11397, 2010.
30. Wik E, Birkeland E, Trovik J, Werner HM, Hoivik EA, Mjos S, Krakstad C, Kusonmano K, Mauland K, Stefansson IM, et al: High phospho-Stathmin(Serine38) expression identifies aggressive endometrial cancer and suggests an association with PI3K inhibition. Clin Cancer Res 19: 2331-2341, 2013.